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and assessing therapeutic modalities. The distinct pattern of mutations and specific location of this unique intraocular tumor have
paved the way for two types of models- those based on genetic mutations, and xenograft models. Retinoblastoma gene knockouts
with an additional loss of p107, p130, p53 and using promoters of Nestin, Chx10, and Pax6 genes show histological phenotypic
changes close to the human form of retinoblastoma. Conditional knockout in specific layers of the developing retina has thrown
light on the origin of this tumor. The use of xenograft models has overcome the obstacle of time delay in the presentation of symp-
toms, which remains a crucial drawback of genetic models. With the advances in molecular and imaging technologies, the current
research aims to develop models that mimic all the features of retinoblastoma inclusive of its initiation, progression and metastasis.
The combination of genetic and xenograft models in retinoblastoma research has and will help to pave way for better understand-
ing of retinoblastoma tumor biology and also in designing and testing effective diagnostic and treatment modalities.
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Animal models are an integral part of preclinical research in
the field of oncology. Non-human tumor models have helped
to identify the course of tumorigenesis and evaluation of diag-
nostic and therapeutic protocols in several human cancers
such as colon, breast, ovarian, and hepatocellular carcinomas,
and ocular melanomas.1–6 In vitro studies have their own
limitations of being conducted devoid of the complex micro-
environment that exists within the human body. Interrogation
of the cellular mechanisms of tumor progression within the
complexity of an organism can help expose the full extent
of pathophysiological changes that take place in neoplasms.
Retinoblastoma
Retinoblastoma is the most common pediatric ocular
malignant tumor occurring in 1 of every 15,000–20,000 livebirths.7,8 This tumor is caused due to inactivation of both
the alleles of the Retinoblastoma (Rb) gene resulting in the
defective formation of pRB protein. pRB is a major tumor sup-
pressor gene that is involved in cell cycle progression, termi-
nal differentiation and DNA replication.9 Loss of pRB activity
in the retinal progenitor cells leads to impaired cell cycle
and uncontrolled cell proliferation. Retinoblastoma manifests
in both unilateral and bilateral forms depending on whether it
is sporadic or familial.10 The understanding of genetic inheri-
tance and advances in diagnostic techniques have not only led
to early diagnosis and genetic prediction but have paved way
for the first of its kind successful preimplantation genetic
diagnosis. Xu et al. reported that it was possible to screen em-
bryos with RB1 mutations, implant a healthy embryo following
in vitro fertilization and subsequently achieve a healthy preg-
nancy and delivery.11 Also, accurate identification of RB1
mutation enables early diagnosis and management of family
members at risk for developing retinoblastoma.12e:
al.com
, India.
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with an overall 3-year survival rate of over 90%.13 However,
it is invariably fatal when left untreated. Prior to the 1990’s,
the standard treatment approach to unilateral RB was enucle-
ation and in the bilateral cases, the treatment typically in-
volved enucleation of the worst eye and external beam
radiation of the other eye. Systemic chemotherapy is now
the treatment of choice for retinoblastoma with an effort to
salvage life, eye, and vision. However, it has been observed
that most of the retinoblastoma cases show continued cellu-
lar activity even in eyes treated with primary systemic chemo-
therapy regimen.14 The prognosis of the disease is affected
by the time of diagnosis and tumor stage.Genetics of retinoblastoma
The predisposition to retinoblastoma was predicted by
Alfred Knudson following statistical analysis of occurrence
in the early 1970’s. Identification of retinoblastoma gene in
1987 confirmed his hypothesis. The bilateral form is heredi-
tary while the unilateral form is generally non-hereditary.15
In the hereditary form, the predisposition to tumor formation
is inherited from a parent who is a carrier of one mutant allele
of the RB1 gene. The presence of one copy of the mutant
gene through germ line transmission predisposes the child
to the loss of second copy at a rate 1000 times more likely
than a spontaneous mutation. This form is more likely to be
multifocal since a copy of mutant RB1 is present in all cells
and mutation of the second allele could occur in several ret-
inal cells. Lack of RB1 in non-retinal cells can also predispose
patients to second malignant neoplasm like osteosarcomas.
Unilateral retinoblastoma involves somatic mutation/loss of
both copies of the RB1 gene in the developing retina and is
generally unifocal.
Tumorigenesis is a multiple step process with a series of
mutations that render cells capable of indefinite proliferation,
resistance to cell death, inducing angiogenesis, evading
growth suppressors, activation of metastasis, evading im-
mune destruction and deregulating cellular energetics. These
neoplastic cells have high predilection toward genomic insta-
bility and triggering inflammatory response.16 In Retinoblas-
toma, the loss of function of the RB1 gene initiates
retinoma leading to genomic instability.17 Retinomas with
non-proliferative areas have extra copies of genes on chro-
mosome 1q, that includes KIF14 and MDM4. Retinoblasto-
mas with increased mitotic activity have multiple copies of
oncogenes such as KIF14, E2F3, DEK and MYCN; in conjunc-
tion to loss of CDH11, a tumor suppressor gene.18,19 The
complete sequence of events promoting retinoblastoma
tumorigenesis is still unknown and techniques such as
whole-genome sequencing of cancers would help unravel
the transformation of benign retinoma to malignant
retinoblastoma.20The need for animal models in retinoblastoma
research
Retinoblastoma cases that warrant enucleation are pre-
sented in an advanced stage and it has been practically
impossible to study the origin of the tumor in human samples
owing to its late presentation and lack of enough viable tis-
sues. Hence, animal models are indispensable tools to helpstudy retinoblastoma origin and tumorigenesis.21,22 Sponta-
neous generation of this tumor seems to be limited only to
humans and several challenges lie in creating an animal mod-
el that mimics retinoblastoma structurally and functionally.Transgenic models of retinoblastoma
During the past three decades several genetic murine
models of retinoblastoma have been developed with moder-
ate to high similarity with human form of the tumor. With the
identification of the role of p107 in mouse retina, the knock-
out of both the genes was necessary to generate retinoblas-
toma in murine eyes.21,23
The retinoblastoma transgenic animal models are detailed
below:LH-beta T-Ag models
This is one of the first and widely studied transgenic mod-
els that was developed in 1990 by Windle JJ et al. This model
expresses the oncogenic SV40 early region under the control
of luteinising hormone b sub-unit (LHb) promoter in the
gonadotrope cells of the anterior pituitary region.24 The
oncogenes present in both Large-T and small-t of the SV40
early region were hypothesized to cause transformation as
these oncoproteins bind to the pRB family, p53 and phospha-
tase pp2A.25 Following this model, retinoblastoma has also
been developed using mice expressing T-Ag/t-Ag from the
IRBP promoter.26,27 These models showed neuronal charac-
teristics of human retinoblastoma histologically but the ques-
tion of cell of origin still remained unanswered until the last
decade. Both Flexner-Wintersteiner and Homer-Wright ro-
settes were observed by light and electron microscopy by
five months of age. However, Pajovic et al. have recently
studied T-Ag protein expression in the retina to track tumor
development from the earliest stages.28 They reported that
Tag expression starts by P8 in the nuclei within the inner nu-
clear layer of the developing retina and then an increase in
number by P21 following which there is a decline until P28.
This decline of TAg expression was coupled with increase in
expression of activated Caspase-3 indicating apoptosis.
Expression of Müller glial markers in these Tag positive cells
was observed at P8 and P9 with the absence of amacrine,
horizontal and bipolar cells. This study concluded that the cell
of origin in these tumors belongs to a sub group of progen-
itor like Muller glial cells that undergoes transformation fol-
lowing Tag expression. Wadhwa et al. developed a Pax6
driven T-Ag model and established a Rb murine cell line
using the tumors from P7 mice.29 Upon characterization, they
have identified the presence of a subpopulation of tumor ini-
tiating cells that express CD133, Nestin and Sox2. The
CD133+ cells were observed to be capable of generating
neurospheres in vitro and form transplantable tumors
in vivo identical to their parent tumor.
The T-Ag model has been widely used in evaluating ther-
apeutics such as local carboplatin therapy, radiation therapy,
cryotherapy, and vascular targeting therapies.30–32 Jockovich
et al. showed that conventional therapies (local carboplatin
chemotherapy and external beam radiotherapy (EBRT)) and
vascular targeting chemicals, such as anecortave acetate, in-
crease apoptotic cell death, while not having a significant ef-
fect on necrosis in this murine model of retinoblastoma.32
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T-antigen-positive mice with retinoblastoma, subconjunctival
delivery of carboplatin in increasing doses effectively inhibits
intraocular tumor growth in a dose-dependent fashion. The
group also observed that cryotherapy does not increase tu-
mor control in this genetic retinoblastoma model.31 Intravi-
treal carboplatin in combination with EBRT also showed
better tumor growth control in these mice.30
Assessing tumor growth in vivo has been a challenge but
studies conducted on these transgenic mice using Optical
coherence tomography (OCT) has allowed the quantification
of tumor growth from the earliest stages of tumor initiation to
advanced tumors.33,34
These models have been invaluable in conducting preclini-
cal studies for developing better therapeutics but one of the
main disadvantages was the use of viral oncoproteins in induc-
ing the tumor, the functions and interactions of which are still
not fully elucidated. This model also showed lack of focal and
clonal tumors characteristic of human retinoblastoma. These
limitations warranted the development of conditional knock-
out models that not only mimicked the histological features
of the human tumor but also its tumorigenesis.
Retinoblastoma knockout models
With the advent of gene knock-out technology, several
groups attempted to generate Rb mouse models by creating
chimeric animals in which the retina alone was constituted of
Rb/cells. But these chimeras did not develop retinoblas-
toma in spite of the Rb/ cells contributing to the developing
central nervous system.35,36 It was however observed that the
developing retina of chimeric Rb/ embryos exhibited ecto-
pic mitoses and extensive cellular degeneration. The role of an-
other protein, p107, was then identified by Robanus-Maandag
et al. to be involved in preventing retinoblastoma in mice lack-
ing a functional Rb gene.23 The protein, p107, shares strong
similarities with the RB1 in terms of its sequence and biochem-
ical parameters.37 It was also reported that in postnatal murine
retinas and their explant cultures lacking Rb, p107 gene was
upregulated, unlike human retina, which supported the
hypothesis that p107 compensates for Rb.38,39
The developmental lethality of Rb/;p107/ was
found to be very high and hence in an attempt to generate
breedable Rb mutant mice, Cre-Lox technology was used
to selectively knock out the genes in the developing retina.40
This study showed that loss of Rb, p107, p53 in photorecep-
tor cells did not lead to any phenotypic changes toward ret-
inoblastoma development. This study paved way for the use
of Cre transgenic technology to create breedable Rb knock-
out models with the help of Nestin, Chx10 and Pax-6 promot-
ers in retinal progenitor and other cells.38,41–43 These models
take 3–9 months to develop detectable tumor and show po-
sitive staining for progenitor, amacrine and Müller glial cells.
Pax-Cre and Nestin-Cre were unsuccessful preclinical models
due to their late onset, low penetrance and cell non-autono-
mous effects and could not be used for further studies. Rb
deletion models with chimera systems and different Cre-
transgenic lines have many similarities in their phenotypes
such as mitotic figures, high levels of cell death in inner retina
from E16.5–18.5,36 ectopic proliferation in retinal ganglion
cell layer,44 photoreceptor degeneration23,38; with the most
prominent effect being the extension of proliferative periodof retinogenesis.38,42,43 It was also observed that upon Rb
deletion, high levels of apoptosis can occur in specific cell
types. For instance, in a-Cre Rblox/lox mice, the ganglion,
bipolar as well as a large majority of rod cells were com-
pletely degenerated.42 This defect was not observed in stud-
ies that used Chx10Cre Rblox/lox retinas, which did not
exhibit bipolar cell death.45 The diverse phenotypic differ-
ences between the models could be explained by the heter-
ogeneity in the genetic background across different strains
and the timing of Cre expression across the cells types.21
The inclusion of an additional mutation of p107 in these
models resulted in the enhancement of several development
phenotypes seen with retinal Rb loss. This revealed that there
is a functional synergy between these family members.23,38,42 A
rise in the embryonic retinal proliferation and apoptosis was
observed in Rb/;p107/ models. Many of the amacrine,
horizontal and Muller cells survived Rb and p107 mutation
and a group of these animals developed retinoblastoma. A
noteworthy point from these models was that since retinoblas-
toma arose from highly apoptosis-sensitive cells, the cell of ori-
gin of these tumors bore inherent resistance to cell death. This
phenomenon is quite similar to human retinoblastomas which
also display a high rate of apoptosis. Markers for amacrine,
horizontal and glial cells have been reported in retinoblasto-
mas lacking Rb and p107.23,43,46,47 The major setbacks of this
model were incomplete penetrance and delayed tumorigene-
sis which led to the generation of Rb/p130 DKO models.
The role of p130 in retinal development, cell cycle exit and
tumor suppression was elucidated in a-Cre Rblox/lox p130/
, NesCre1 Rblox/lox p130/ and in Rb/p130/ chi-
meras.38,43,48 Histological defects in the embryonic retinal
development observed in the NesCre1 Rb/p107 DKO retinas
were absent in these models [38]. Chimeric animals lacking
Rb and p130, NesCre1 Rblox/lox p130/ and a-Cre
Rblox/lox p130/mice all form retinoblastomas with heter-
ogeneous marker expression including horizontal and ama-
crine markers.38,43,48 a-Cre Rblox/lox p130-/-animals
showed lesions resembling retinoblastoma, consistent with
Homer-Wright rosettes, that were observed as early as
PND21 to PND31 at the extreme periphery of the retina.43
These tumors then grow to fill the vitreous cavity and a por-
tion of the growing cells extend into the brain by invading the
optic nerve. These findings are similar to cases with advanced
retinoblastoma metastasizing to the brain. The a-Cre Rb /
p130 DKO mouse is a pertinent model for studying advanced
retinoblastoma given the rapid tumor progression and
metastasis. Rb/p130 DKO retinoblastomas appear similar to
Rb/p107 DKO retinoblastomas upon histological examina-
tion, and both resemble human retinoblastomas with neurob-
lastic differentiation. To further elucidate the role of Rb family
members-Rb1, p107 and p130; Ajioka et al. generated mice
that express a single copy of each in the developing retina.49
They observed that in p107(+/) retina, the horizontal neu-
rons initially differentiate normally but after several weeks,
they re-enter the cell cycle, clonally expand and form bilateral
retinoblastoma that metastasized into the bone marrow. The
horizontal cells were not affected in the other knock-out mice
(Rb(+/);p107(/);p130(/) or Rb(/);p107(/
);p130(+/)), thereby indicating that a single copy of Rb
or p130 controlled horizontal cell proliferation and prevented
its clonal expansion. This study reported for the first time that
differentiated neurons were capable of re-entering the cell
Figure 1. Genetic Models of Retinoblastoma with their key features.
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toma arises from dedifferentiation of horizontal cells.49 An
extensive study was done recently by McEvoy J et al. on six
mouse lines that develop retinoblastoma using the Chx10-
Cre system.50 The knockout mice were found to be similar
to each other and to human retinoblastoma in their molecular
profiles. The cell type signatures, neuroanatomic, neuro-
chemical and morphometric features most common to hu-
man and mice models belonged to the amacrine cell
differentiation. The summary of established Retinoblastoma
knock-out models along with some of their salient features
are illustrated in Fig. 1.
The transgenic models have also been used extensively in
assessing existing and novel therapeutic modalities. Laurie
et al. showed that in a genetic model generated by injecting
a replication-incompetent retrovirus encoding the E1A 13S
oncogene into newborn p53-deficient mice, which induced
clonal retinal tumors arising from one to five individual foci;
the combination of topotecan with carboplatin would be a
potent alternative to the current triple drug therapy (carbo-
platin/etoposide/vincristine).51
Xenograft models of retinoblastoma
The development of Rb xenograft models has facilitated
rapid in vivo assessment of cell lines and tumor tissues inimmunocompromised animals. One of the early studies was
done in immunosuppressed rabbits by McFall et al. where
an inoculum of 107 cells from Rb cell lines, Y79 and WERI-
Rb, was injected in the anterior chamber of the eye which re-
sulted in tumor growth.52 The tumors were found to exhibit
maximum growth as observed by slit-lamp between day
17–22 post injection. Histological sections confirmed the
presence of tumor cells along with corneal vascularization
and edema. Kang et al. developed a rabbit model of retino-
blastoma using 106 WERI-Rb cells injected in the sub-retinal
space.53 They reported tumor, growth detectable with fun-
doscopy, starting from week 1 post injection with vasculariza-
tion starting from week 5 and continued tumor growth up to
week 8. The histological sections confirmed the intraocular
tumor in the sub-retinal space near the optic nerve and vitre-
ous cavity lesions with lack of metastatic phenotype. Blood
vessels surrounded by viable tumor cells and necrotic areas
similar to that of human retinoblastoma were also
observed.53 The major limitation of this model was that the
tumors grow from the sub-retinal space and not from the
retina.
Furthermore, tumor growth was achieved in athymic nude
mice when primary cells and Rb cell line-Y79 and WERI were
injected intraocularly which were reproducible.54,55 The pri-
mary tumors that grew within the eyes remained histologi-
cally similar to the original tumors. These tumors could be
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similar growth patterns were achieved. Chévez-Barrios et al.
confirmed that Y79 cells represented metastatic phenotype
showing invasion into the retina, subretinal space, choroid,
optic nerve head, and anterior chamber of the eye, progress-
ing into the subarachnoid space and focally invading the
brain. On the contrary, WERI cells produced tumors that
were localized in the eye with only anterior choroidal invasion
at late stages.56 Cell number ranging from 103 to 107 injected
intraocularly (intravitreal, anterior chamber, and subretinal)
showed positive tumor growth in several xenograft models
of retinoblastoma. These models are widely used for testing
the efficacy of existing and new chemotherapeutic agents
and photodynamic therapy.51,57,58
Advances in non-invasive methods of studying in vivo tumor
growth and distant metastasis have been achieved using xeno-
graft models of retinoblastoma. Some of them include micro-
computed tomography (microCT), magnetic resonance
imaging (MRI), positron emission tomography, fluorescence
imaging and bioluminescence imaging (BLI) .Xunda Ji et al.
showed that using BLI it was possible to monitor intraocular tu-
mor growth and metastasis in vivo. In their study, Y79-GFP-luc
cells and HXO-Rb44-GFP-luc cells were used to induce tumors
in nude mice. All the unilateral sub-retinal injected mice devel-
oped retinoblastoma which did not exhibit metastasis. How-
ever, in one of the bilateral subretinal injected mice, brain
metastasis was observed 10 weeks post initial detection of
luciferase activity.59 Since these tumors failed to produce dis-
tant metastasis, the authors injected the labeled cells directly
into the systemic circulation. They noted that a large number
of the mice receiving intracardiac injection formed systemic
metastatic disease (9/15) whereas of those mice receiving tail
vein injection, only 1 mouse (of 16) developed metastasis.
The sites for metastasis were most commonly observed to
the lymphatic system (47%), bone (40%), and brain (13%).59
The major setback to using xenograft models is that the
tumor microenvironment is altered when human cells are in-
jected into the rodent/rabbit eyes. This could possibly lead
to differences in the genetic heterogeneity and derangement
of normal tumor niche. Therefore, these models should be
considered with caution and as an intermediate between
in vitro cell culture and retinoblastoma genetic models.
Summary and future directions
Retinoblastoma research has progressed rapidly in the last
three decades owing to the improvement in developing ani-
mal models that closely resemble the human malignancy. In-
sights into the role of tumor suppression by the Rb gene have
also helped in understanding the generation of Rb tumors
and its course of tumorigenesis. An ideal Retinoblastoma ani-
mal model should exhibit all the features of the human form
that include initiation at the cell of origin, clonal expansion,
intraocular spread (endophytic/exophytic), and exophytic
spread (contiguous through optic nerve and hematogenous
spread. Generation of these animal models would pave way
for developing powerful diagnostic tools by marker studies
and also in testing the efficacy of various treatment modali-
ties and predicting prognostic markers.
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